These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12840709)

  • 1. Induction-maintenance antiretroviral strategies to reduce long-term toxicity.
    Kelly M
    J HIV Ther; 2003 Feb; 8(1):11-4. PubMed ID: 12840709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching effective antiretroviral therapy: a review.
    Drechsler H; Powderly WG
    Clin Infect Dis; 2002 Nov; 35(10):1219-30. PubMed ID: 12410482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
    Müller AD; Myer L; Jaspan H
    Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily therapies.
    Carey D
    J HIV Ther; 2003 Feb; 8(1):7-11. PubMed ID: 12840708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and concerns of simplification strategies in HIV-infected patients.
    Negredo E; Bonjoch A; Clotet B
    J Antimicrob Chemother; 2006 Aug; 58(2):235-42. PubMed ID: 16807250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.
    Bucher HC; Young J; Battegay M
    J Antimicrob Chemother; 2004 Aug; 54(2):303-5. PubMed ID: 15269200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic resistance tests for the management of patients at simplification of highly active antiretroviral therapy.
    Suter F; Ghinelli F
    Scand J Infect Dis Suppl; 2003; 106():82-5. PubMed ID: 15000592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch strategies in patients on effective HAART.
    Maggiolo F; Ripamonti D; Suter F
    J Antimicrob Chemother; 2005 Jun; 55(6):821-3. PubMed ID: 15849261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Revised guideline "Antiretroviral Treatment"].
    Werkgroep antiretrovirale behandeling van de Nederlandse Vereniging van Aids Behandelaren
    Ned Tijdschr Geneeskd; 2005 Oct; 149(43):2399-405. PubMed ID: 16277129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
    Calza L; Manfredi R; Chiodo F
    J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment interruption in HIV therapy: a SMART strategy?
    Jülg B; Goebel FD
    Infection; 2006 Jun; 34(3):186-8. PubMed ID: 16804667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long-term consequences of antiretroviral therapy: a review.
    Boyd M; Reiss P
    J HIV Ther; 2006 Jun; 11(2):26-35. PubMed ID: 16981593
    [No Abstract]   [Full Text] [Related]  

  • 17. Improvements in antiretroviral therapy outcomes over calendar time.
    Boyd MA
    Curr Opin HIV AIDS; 2009 May; 4(3):194-9. PubMed ID: 19532050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term consequences of antiretroviral therapy.
    Smith D
    J HIV Ther; 2006 Jun; 11(2):24-5. PubMed ID: 16981592
    [No Abstract]   [Full Text] [Related]  

  • 19. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
    Justesen US
    Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
    Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
    AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.